Apocrine carcinoma of the breast: Review

[1] Mossler JA, Barton TK, Brinkhous AD, McCarty KS, Moylan JA, McCarty KS Jr. Apocrine differentiation in human mammary carcinoma. Cancer. 1980;46(11):2463–2471. doi:10.1002/1097-0142(19801201)46:11<2463::aidcncr2820461127>3.0.co;2-# MosslerJA BartonTK BrinkhousAD McCartyKS MoylanJA McCartyKSJr Apocrine differentiation in human mammary carcinoma Cancer. 1980 46 11 2463 2471 10.1002/1097-0142(19801201)46:11<2463::aidcncr2820461127>3.0.co;2-# Open DOISearch in Google Scholar

[2] Eusebi V, Millis RR, Cattani MG, Bussolati G, Azzopardi JG. Apocrine carcinoma of the breast. A morphologic and immunocytochemical study [published correction appears in Am J Pathol 1986 Sep;124(3): following 563]. Am J Pathol. 1986;123(3):532–541. EusebiV MillisRR CattaniMG BussolatiG AzzopardiJG Apocrine carcinoma of the breast. A morphologic and immunocytochemical study [published correction appears in Am J Pathol 1986 Sep;124(3): following 563] Am J Pathol. 1986 123 3 532 541 Search in Google Scholar

[3] Durham JR, Fechner RE. The Histologic Spectrum of Apocrine Lesions of the Breast. Am J Clin Pathol. 2000;113(suppl_1):S3–S18. doi:10.1309/7A2P-YMWJ-B1PD-UDN9 DurhamJR FechnerRE The Histologic Spectrum of Apocrine Lesions of the Breast Am J Clin Pathol. 2000 113 suppl_1 S3 S18 10.1309/7A2P-YMWJ-B1PD-UDN9 Open DOISearch in Google Scholar

[4] Vranic S, Schmitt F, Sapino A, et al. Apocrine carcinoma of the breast: a comprehensive review. Histol Histopathol. 2013;28(11):1393–1409. doi:10.14670/HH-28.1393 VranicS SchmittF SapinoA Apocrine carcinoma of the breast: a comprehensive review Histol Histopathol. 2013 28 11 1393 1409 10.14670/HH-28.1393 Open DOISearch in Google Scholar

[5] Selim AG, El-Ayat G, Wells CA. c-erbB2 oncoprotein expression, gene amplification, and chromosome 17 aneusomy in apocrine adenosis of the breast. J Pathol. 2000;191(2):138–142. doi:10.1002/(SICI)1096-9896(200006)191:2<138::AID-PATH611>3.0.CO;2-J SelimAG El-AyatG WellsCA c-erbB2 oncoprotein expression, gene amplification, and chromosome 17 aneusomy in apocrine adenosis of the breast J Pathol. 2000 191 2 138 142 10.1002/(SICI)1096-9896(200006)191:2<138::AID-PATH611>3.0.CO;2-J Open DOISearch in Google Scholar

[6] Choi J, Jung WH, Koo JS. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers. Histol Histopathol. 2012;27(11):1481–1493. doi:10.14670/HH-27.1481 ChoiJ JungWH KooJS Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers Histol Histopathol. 2012 27 11 1481 1493 10.14670/HH-27.1481 Open DOISearch in Google Scholar

[7] Vranic S, Tawfik O, Palazzo J, et al. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol. 2010;23(5):644–653. doi:10.1038/modpathol.2010.50 VranicS TawfikO PalazzoJ EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast Mod Pathol. 2010 23 5 644 653 10.1038/modpathol.2010.50 Open DOISearch in Google Scholar

[8] Dellapasqua S, Maisonneuve P, Viale G, et al. Immunohistochemically defined subtypes and outcome of apocrine breast cancer. Clin Breast Cancer. 2013;13(2):95–102. doi:10.1016/j.clbc.2012.11.004 DellapasquaS MaisonneuveP VialeG Immunohistochemically defined subtypes and outcome of apocrine breast cancer Clin Breast Cancer. 2013 13 2 95 102 10.1016/j.clbc.2012.11.004 Open DOISearch in Google Scholar

[9] Matsuo K, Fukutomi T, Tsuda H, Kanai Y, Tanaka SA, Nanasawa T. Apocrine Carcinoma of the Breast: Clinicopathological Analysis and Histological Subclassification of 12 Cases. Breast Cancer. 1998;5(3):279–284. doi:10.1007/BF02966708 MatsuoK FukutomiT TsudaH KanaiY TanakaSA NanasawaT Apocrine Carcinoma of the Breast: Clinicopathological Analysis and Histological Subclassification of 12 Cases Breast Cancer. 1998 5 3 279 284 10.1007/BF02966708 Open DOISearch in Google Scholar

[10] Honma N, Sakamoto G, Akiyama F, et al. Breast carcinoma in women over the age of 85: distinct histological pattern and androgen, oestrogen, and progesterone receptor status. Histopathology. 2003;42(2):120–127. doi:10.1046/j.1365-2559.2003.01542.x HonmaN SakamotoG AkiyamaF Breast carcinoma in women over the age of 85: distinct histological pattern and androgen, oestrogen, and progesterone receptor status Histopathology. 2003 42 2 120 127 10.1046/j.1365-2559.2003.01542.x Open DOISearch in Google Scholar

[11] Gilles R, Lesnik A, Guinebretière JM, et al. Apocrine carcinoma: clinical and mammographic features. Radiology. 1994;190(2):495–497. doi:10.1148/radiology.190.2.8284405 GillesR LesnikA GuinebretièreJM Apocrine carcinoma: clinical and mammographic features Radiology. 1994 190 2 495 497 10.1148/radiology.190.2.8284405 Open DOISearch in Google Scholar

[12] D’Arcy C, Quinn C. Apocrine lesions of the breast: part 1 of a two-part review: benign, atypical and in situ apocrine proliferations of the breast. J Clin Pathol. 2019;72(1):1–6. doi:10.1136/jclinpath-2018-205484 D’ArcyC QuinnC Apocrine lesions of the breast: part 1 of a two-part review: benign, atypical and in situ apocrine proliferations of the breast J Clin Pathol. 2019 72 1 1 6 10.1136/jclinpath-2018-205484 Open DOISearch in Google Scholar

[13] Tavassoli FA, Norris HJ. Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases. Mod Pathol. 1994;7(8):813–818. TavassoliFA NorrisHJ Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases Mod Pathol. 1994 7 8 813 818 Search in Google Scholar

[14] Carter DJ, Rosen PP. Atypical apocrine metaplasia in sclerosing lesions of the breast: a study of 51 patients. Mod Pathol. 1991;4(1):1–5. CarterDJ RosenPP Atypical apocrine metaplasia in sclerosing lesions of the breast: a study of 51 patients Mod Pathol. 1991 4 1 1 5 Search in Google Scholar

[15] Fuehrer N, Hartmann L, Degnim A, et al. Atypical apocrine adenosis of the breast: long-term follow-up in 37 patients. Arch Pathol Lab Med. 2012;136(2):179–182. doi:10.5858/arpa.2011-0225-OA FuehrerN HartmannL DegnimA Atypical apocrine adenosis of the breast: long-term follow-up in 37 patients Arch Pathol Lab Med. 2012 136 2 179 182 10.5858/arpa.2011-0225-OA Open DOISearch in Google Scholar

[16] Calhoun, B.C., & Booth, C.N. (2014). Atypical apocrine adenosis diagnosed on breast core biopsy: implications for management. Human pathology, 45 10, 2130–5. CalhounB.C. BoothC.N. 2014 Atypical apocrine adenosis diagnosed on breast core biopsy: implications for management Human pathology 45 10 2130 5 Search in Google Scholar

[17] Leal C, Henrique R, Monteiro P, et al. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. Hum Pathol. 2001;32(5):487–493. doi:10.1053/hupa.2001.24327 LealC HenriqueR MonteiroP Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers Hum Pathol. 2001 32 5 487 493 10.1053/hupa.2001.24327 Open DOISearch in Google Scholar

[18] Chen YY, Hwang ES, Roy R, et al. Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am J Surg Pathol. 2009;33(11):1683–1694. doi:10.1097/PAS.0b013e3181b18a89 ChenYY HwangES RoyR Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast Am J Surg Pathol. 2009 33 11 1683 1694 10.1097/PAS.0b013e3181b18a89 Open DOISearch in Google Scholar

[19] Xu Y, Zhang W, He J, et al. Nomogram for predicting overall survival in patients with triple-negative apocrine breast cancer: Surveillance, epidemiology, and end results-based analysis. Breast. 2022;66:8–14. doi:10.1016/j.breast.2022.08.011 XuY ZhangW HeJ Nomogram for predicting overall survival in patients with triple-negative apocrine breast cancer: Surveillance, epidemiology, and end results-based analysis Breast. 2022 66 8 14 10.1016/j.breast.2022.08.011 Open DOISearch in Google Scholar

[20] Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24(29):4660–4671. doi:10.1038/sj.onc.1208561 FarmerP BonnefoiH BecetteV Identification of molecular apocrine breast tumours by microarray analysis Oncogene. 2005 24 29 4660 4671 10.1038/sj.onc.1208561 Open DOISearch in Google Scholar

[21] D’Arcy C, Quinn CM. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast. J Clin Pathol. 2019;72(1):7–11. doi:10.1136/jclinpath-2018-205485 D’ArcyC QuinnCM Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast J Clin Pathol. 2019 72 1 7 11 10.1136/jclinpath-2018-205485 Open DOISearch in Google Scholar

[22] Vranic S, Gatalica Z, Deng H, et al. ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast. J Clin Pathol. 2011;64(1):54–57. doi:10.1136/jcp.2010.082776 VranicS GatalicaZ DengH ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast J Clin Pathol. 2011 64 1 54 57 10.1136/jcp.2010.082776 Open DOISearch in Google Scholar

[23] Bratthauer GL, Lininger RA, Man YG, Tavassoli FA. Androgen and estrogen receptor mRNA status in apocrine carcinomas. Diagn Mol Pathol. 2002;11(2):113–118. doi:10.1097/00019606-200206000-00008 BratthauerGL LiningerRA ManYG TavassoliFA Androgen and estrogen receptor mRNA status in apocrine carcinomas Diagn Mol Pathol. 2002 11 2 113 118 10.1097/00019606-200206000-00008 Open DOISearch in Google Scholar

[24] Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A. 2006;103(24):9063–9068. doi:10.1073/pnas.0603339103 WangZ ZhangX ShenP LoggieBW ChangY DeuelTF A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling Proc Natl Acad Sci U S A. 2006 103 24 9063 9068 10.1073/pnas.0603339103 Open DOISearch in Google Scholar

[25] Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z, Wang ZY. A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene. 2011;30(7):770–780. doi:10.1038/onc.2010.458 ZhangXT KangLG DingL VranicS GatalicaZ WangZY A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells Oncogene. 2011 30 7 770 780 10.1038/onc.2010.458 Open DOISearch in Google Scholar

[26] Lehmann-Che J, Hamy AS, Porcher R, et al. Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res. 2013;15(3):R37. Published 2013 May 11. doi:10.1186/bcr3421 Lehmann-CheJ HamyAS PorcherR Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15 Breast Cancer Res. 2013 15 3 R37 Published 2013 May 11. 10.1186/bcr3421 Open DOISearch in Google Scholar

[27] Wells CA, El-Ayat GA. Non-operative breast pathology: apocrine lesions. J Clin Pathol. 2007;60(12):1313–1320. doi:10.1136/jcp.2006.040626 WellsCA El-AyatGA Non-operative breast pathology: apocrine lesions J Clin Pathol. 2007 60 12 1313 1320 10.1136/jcp.2006.040626 Open DOISearch in Google Scholar

[28] Arciero CA, Diehl AH 3rd, Liu Y, et al. Triple-negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple-negative breast cancers. J Surg Oncol. 2020;122(6):1232–1239. doi:10.1002/jso.26129 ArcieroCA DiehlAH3rd LiuY Triple-negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple-negative breast cancers J Surg Oncol. 2020 122 6 1232 1239 10.1002/jso.26129 Open DOISearch in Google Scholar

[29] Ismail S, Kherbek H, Skef J, Zahlouk N, Abdulal R, Alshehabi Z. Triple-negative apocrine carcinoma as a rare cause of a breast lump in a Syrian female: a case report and review of the literature. BMC Womens Health. 2021;21(1):396. Published 2021 Nov 25. doi:10.1186/s12905-021-01539-3 IsmailS KherbekH SkefJ ZahloukN AbdulalR AlshehabiZ Triple-negative apocrine carcinoma as a rare cause of a breast lump in a Syrian female: a case report and review of the literature BMC Womens Health. 2021 21 1 396 Published 2021 Nov 25. 10.1186/s12905-021-01539-3 Open DOISearch in Google Scholar

[30] Darb-Esfahani S, von Minckwitz G, Denkert C, et al. Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes. BMC Cancer. 2014;14:546. Published 2014 Jul 28. doi:10.1186/1471-2407-14-546 Darb-EsfahaniS von MinckwitzG DenkertC Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes BMC Cancer. 2014 14 546 Published 2014 Jul 28. 10.1186/1471-2407-14-546 Open DOISearch in Google Scholar

[31] Vranic S, Marchiò C, Castellano I, et al. Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast. Hum Pathol. 2015;46(9):1350–1359. doi:10.1016/j.humpath.2015.05.017 VranicS MarchiòC CastellanoI Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast Hum Pathol. 2015 46 9 1350 1359 10.1016/j.humpath.2015.05.017 Open DOISearch in Google Scholar

[32] Mazoujian G, Pinkus GS, Davis S, Haagensen DE Jr. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol. 1983;110(2):105–112. MazoujianG PinkusGS DavisS HaagensenDEJr Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features Am J Pathol. 1983 110 2 105 112 Search in Google Scholar

[33] Honma N, Takubo K, Akiyama F, et al. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Histopathology. 2005;47(2):195–201. doi:10.1111/j.1365-2559.2005.02181.x HonmaN TakuboK AkiyamaF Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast Histopathology. 2005 47 2 195 201 10.1111/j.1365-2559.2005.02181.x Open DOISearch in Google Scholar

[34] Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 2004;6(5):517–527. doi:10.1016/j.ccr.2004.09.031 MellinghoffIK VivancoI KwonA TranC WongvipatJ SawyersCL HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability Cancer Cell. 2004 6 5 517 527 10.1016/j.ccr.2004.09.031 Open DOISearch in Google Scholar

[35] Darb-Esfahani S, von Minckwitz G, Denkert C, et al. Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes. BMC Cancer. 2014;14:546. Published 2014 Jul 28. doi:10.1186/1471-2407-14-546 Darb-EsfahaniS von MinckwitzG DenkertC Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes BMC Cancer. 2014 14 546 Published 2014 Jul 28. 10.1186/1471-2407-14-546 Open DOISearch in Google Scholar

[36] Nakamura H, Kukita Y, Kunimasa K, et al. α-Methylacyl-CoA racemase: a useful immunohistochemical marker of breast carcinoma with apocrine differentiation. Hum Pathol. 2021;116:39–48. doi:10.1016/j.humpath.2021.07.005 NakamuraH KukitaY KunimasaK α-Methylacyl-CoA racemase: a useful immunohistochemical marker of breast carcinoma with apocrine differentiation Hum Pathol. 2021 116 39 48 10.1016/j.humpath.2021.07.005 Open DOISearch in Google Scholar

[37] Sun X, Zuo K, Yao Q, et al. Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas. Mod Pathol. 2020;33(12):2473–2482. doi:10.1038/s41379-020-0589-x SunX ZuoK YaoQ Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas Mod Pathol. 2020 33 12 2473 2482 10.1038/s41379-020-0589-x Open DOISearch in Google Scholar

[38] Shi W, Jiang T, Nuciforo P, et al. Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial [published correction appears in Ann Oncol. 2018 Apr 1;29(4):1075] [published correction appears in Ann Oncol. 2018 Oct 1;29(10):2152] [published correction appears in Ann Oncol. 2019 Jan 9;:]. Ann Oncol. 2017;28(1):128–135. doi:10.1093/annonc/mdw434 ShiW JiangT NuciforoP Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial [published correction appears in Ann Oncol. 2018 Apr 1;29(4):1075] [published correction appears in Ann Oncol. 2018 Oct 1;29(10):2152] [published correction appears in Ann Oncol. 2019 Jan 9;:] Ann Oncol. 2017 28 1 128 135 10.1093/annonc/mdw434 Open DOISearch in Google Scholar

[39] McNamara KM, Yoda T, Miki Y, et al. Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation. Cancer Sci. 2013;104(5):639–646. doi:10.1111/cas.12121 McNamaraKM YodaT MikiY Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation Cancer Sci. 2013 104 5 639 646 10.1111/cas.12121 Open DOISearch in Google Scholar

[40] O’Malley FP, Bane A. An update on apocrine lesions of the breast. Histopathology. 2008;52(1):3–10. doi:10.1111/j.1365-2559.2007.02888.x O’MalleyFP BaneA An update on apocrine lesions of the breast Histopathology. 2008 52 1 3 10 10.1111/j.1365-2559.2007.02888.x Open DOISearch in Google Scholar

[41] Yerushalmi R, Hayes MM, Gelmon KA. Breast carcinoma--rare types: review of the literature. Ann Oncol. 2009;20(11):1763–1770. doi:10.1093/annonc/mdp245 YerushalmiR HayesMM GelmonKA Breast carcinoma--rare types: review of the literature Ann Oncol. 2009 20 11 1763 1770 10.1093/annonc/mdp245 Open DOISearch in Google Scholar

[42] Dusenbery AC, Maniaci JL, Hillerson ND, Dill EA, Bullock TN, Mills AM. MHC Class I Loss in Triple-negative Breast Cancer: A Potential Barrier to PD-1/PD-L1 Checkpoint Inhibitors. Am J Surg Pathol. 2021;45(5):701–707. doi:10.1097/PAS.0000000000001653 DusenberyAC ManiaciJL HillersonND DillEA BullockTN MillsAM MHC Class I Loss in Triple-negative Breast Cancer: A Potential Barrier to PD-1/PD-L1 Checkpoint Inhibitors Am J Surg Pathol. 2021 45 5 701 707 10.1097/PAS.0000000000001653 Open DOISearch in Google Scholar

[43] Vranic S, Gatalica Z. An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast. Clin Breast Cancer. 2022;22(4):e576–e585. doi:10.1016/j.clbc.2021.12.009 VranicS GatalicaZ An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast Clin Breast Cancer. 2022 22 4 e576 e585 10.1016/j.clbc.2021.12.009 Open DOISearch in Google Scholar

[44] Arciero CA, Diehl AH 3rd, Liu Y, et al. Triple-negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple-negative breast cancers. J Surg Oncol. 2020;122(6):1232–1239. doi:10.1002/jso.26129 ArcieroCA DiehlAH3rd LiuY Triple-negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple-negative breast cancers J Surg Oncol. 2020 122 6 1232 1239 10.1002/jso.26129 Open DOISearch in Google Scholar

[45] Mills AM, E Gottlieb C, M Wendroth S, M Brenin C, Atkins KA. Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers. Am J Surg Pathol. 2016;40(8):1109–1116. doi:10.1097/PAS.0000000000000671 MillsAM GottliebCE WendrothSM BreninCM AtkinsKA Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers Am J Surg Pathol. 2016 40 8 1109 1116 10.1097/PAS.0000000000000671 Open DOISearch in Google Scholar

[46] Xu Y, Zhang W, He J, et al. Nomogram for predicting overall survival in patients with triple-negative apocrine breast cancer: Surveillance, epidemiology, and end results-based analysis. Breast. 2022;66:8–14. doi:10.1016/j.breast.2022.08.011 XuY ZhangW HeJ Nomogram for predicting overall survival in patients with triple-negative apocrine breast cancer: Surveillance, epidemiology, and end results-based analysis Breast. 2022 66 8 14 10.1016/j.breast.2022.08.011 Open DOISearch in Google Scholar

[47] Wu W, Wu M, Peng G, Shi D, Zhang J. Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study. Cancer Med. 2019;8(18):7523–7531. doi:10.1002/cam4.2634 WuW WuM PengG ShiD ZhangJ Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study Cancer Med. 2019 8 18 7523 7531 10.1002/cam4.2634 Open DOISearch in Google Scholar

[48] Meattini I, Pezzulla D, Saieva C, et al. Triple Negative Apocrine Carcinomas as a Distinct Subtype of Triple Negative Breast Cancer: A Case-control Study. Clin Breast Cancer. 2018;18(5):e773–e780. doi:10.1016/j.clbc.2018.02.012 MeattiniI PezzullaD SaievaC Triple Negative Apocrine Carcinomas as a Distinct Subtype of Triple Negative Breast Cancer: A Case-control Study Clin Breast Cancer. 2018 18 5 e773 e780 10.1016/j.clbc.2018.02.012 Open DOISearch in Google Scholar

[49] Japaze H, Emina J, Diaz C, et al. ‘Pure’ invasive apocrine carcinoma of the breast: a new clinicopathological entity?. Breast. 2005;14(1):3–10. doi:10.1016/j.breast.2004.06.003 JapazeH EminaJ DiazC ‘Pure’ invasive apocrine carcinoma of the breast: a new clinicopathological entity? Breast. 2005 14 1 3 10 10.1016/j.breast.2004.06.003 Open DOISearch in Google Scholar

[50] Imamovic D, Bilalovic N, Skenderi F, et al. A clinicopathologic study of invasive apocrine carcinoma of the breast: A single-center experience. Breast J. 2018;24(6):1105–1108. doi:10.1111/tbj.13140 ImamovicD BilalovicN SkenderiF A clinicopathologic study of invasive apocrine carcinoma of the breast: A single-center experience Breast J. 2018 24 6 1105 1108 10.1111/tbj.13140 Open DOISearch in Google Scholar

[51] Choi JE, Kang SH, Lee SJ, Bae YK. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol. 2015;22(1):82–89. doi:10.1245/s10434-014-3984-z ChoiJE KangSH LeeSJ BaeYK Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer Ann Surg Oncol. 2015 22 1 82 89 10.1245/s10434-014-3984-z Open DOISearch in Google Scholar

[52] He J, Peng R, Yuan Z, et al. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. 2012;29(2):406–410. doi:10.1007/s12032-011-9832-0 HeJ PengR YuanZ Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray Med Oncol. 2012 29 2 406 410 10.1007/s12032-011-9832-0 Open DOISearch in Google Scholar

[53] Ni M, Chen Y, Lim E, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 2011;20(1):119–131. doi:10.1016/j.ccr.2011.05.026 NiM ChenY LimE Targeting androgen receptor in estrogen receptor-negative breast cancer Cancer Cell. 2011 20 1 119 131 10.1016/j.ccr.2011.05.026 Open DOISearch in Google Scholar

[54] Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor-negative breast cancer. Neoplasia. 2008;10(6):542–548. doi:10.1593/neo.08274 NaderiA Hughes-DaviesL A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor-negative breast cancer Neoplasia. 2008 10 6 542 548 10.1593/neo.08274 Open DOISearch in Google Scholar

[55] Naderi A, Meyer M, Dowhan DH. Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer. Neoplasia. 2012;14(4):283–296. doi:10.1593/neo.12294 NaderiA MeyerM DowhanDH Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer Neoplasia. 2012 14 4 283 296 10.1593/neo.12294 Open DOISearch in Google Scholar

[56] Lee YT, Liu HM, Lee LH, et al. The polymorphism of CAG repeats in the androgen receptor gene and breast cancer mortality. Cancer Biomark. 2015;15(6):815–822. doi:10.3233/CBM-150525 LeeYT LiuHM LeeLH The polymorphism of CAG repeats in the androgen receptor gene and breast cancer mortality Cancer Biomark. 2015 15 6 815 822 10.3233/CBM-150525 Open DOISearch in Google Scholar

[57] Kasami M, Gobbi H, Dupont WD, Simpson JF, Page DL, Vnencak-Jones CL. Androgen receptor CAG repeat lengths in ductal carcinoma in situ of breast, longest in apocrine variety. Breast. 2000;9(1):23–27. doi:10.1054/brst.1999.0070 KasamiM GobbiH DupontWD SimpsonJF PageDL Vnencak-JonesCL Androgen receptor CAG repeat lengths in ductal carcinoma in situ of breast, longest in apocrine variety Breast. 2000 9 1 23 27 10.1054/brst.1999.0070 Open DOISearch in Google Scholar

[58] Santonja A, Sánchez-Muñoz A, Lluch A, et al. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget. 2018;9(41):26406–26416. Published 2018 May 29. doi:10.18632/oncotarget.25413 SantonjaA Sánchez-MuñozA LluchA Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy Oncotarget. 2018 9 41 26406 26416 Published 2018 May 29. 10.18632/oncotarget.25413 Open DOISearch in Google Scholar

[59] Echavarria I, López-Tarruella S, Picornell A, et al. Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. Clin Cancer Res. 2018;24(8):1845–1852. doi:10.1158/1078-0432.CCR-17-1912 EchavarriaI López-TarruellaS PicornellA Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification Clin Cancer Res. 2018 24 8 1845 1852 10.1158/1078-0432.CCR-17-1912 Open DOISearch in Google Scholar

[60] Mohammed AA, Elsayed FM, Algazar M, Rashed HE, Anter AH. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response. Asian Pac J Cancer Prev. 2020;21(2):563–568. Published 2020 Feb 1. doi:10.31557/APJCP.2020.21.2.563 MohammedAA ElsayedFM AlgazarM RashedHE AnterAH Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response Asian Pac J Cancer Prev. 2020 21 2 563 568 Published 2020 Feb 1. 10.31557/APJCP.2020.21.2.563 Open DOISearch in Google Scholar

[61] Bonnefoi H, MacGrogan G, Poncet C, et al. Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. Br J Cancer. 2019;120(9):913–921. doi:10.1038/s41416-019-0420-y BonnefoiH MacGroganG PoncetC Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes Br J Cancer. 2019 120 9 913 921 10.1038/s41416-019-0420-y Open DOISearch in Google Scholar

[62] Altundag K. De-escalating systemic chemotherapy might be considered for pure triple negative apocrine breast cancer patients. J BUON. 2019;24(2):864. AltundagK De-escalating systemic chemotherapy might be considered for pure triple negative apocrine breast cancer patients J BUON. 2019 24 2 864 Search in Google Scholar

[63] Vranic S, Feldman R, Gatalica Z. Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers. Bosn J Basic Med Sci. 2017;17(1):9–11. Published 2017 Feb 21. doi:10.17305/bjbms.2016.1811 VranicS FeldmanR GatalicaZ Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers Bosn J Basic Med Sci. 2017 17 1 9 11 Published 2017 Feb 21. 10.17305/bjbms.2016.1811 Open DOISearch in Google Scholar

[64] Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013;19(19):5505–5512. doi:10.1158/1078-0432.CCR-12-3327 GucalpA TolaneyS IsakoffSJ Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer Clin Cancer Res. 2013 19 19 5505 5512 10.1158/1078-0432.CCR-12-3327 Open DOISearch in Google Scholar

[65] Lu Q, Xia W, Lee K, et al. Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer. Oncologist. 2020;25(1):21–e15. doi:10.1634/theoncologist.2019-0564 LuQ XiaW LeeK Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer Oncologist. 2020 25 1 21 e15 10.1634/theoncologist.2019-0564 Open DOISearch in Google Scholar

[66] Cipriano É, Mesquita A. Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer. Breast Cancer (Auckl). 2021;15:11782234211002491. Published 2021 Mar 22. doi:10.1177/11782234211002491 CiprianoÉ MesquitaA Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer Breast Cancer (Auckl). 2021 15 11782234211002491. Published 2021 Mar 22. 10.1177/11782234211002491 Open DOISearch in Google Scholar

[67] Bonnefoi H, Grellety T, Tredan O, et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol. 2016;27(5):812–818. doi:10.1093/annonc/mdw067 BonnefoiH GrelletyT TredanO A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1) Ann Oncol. 2016 27 5 812 818 10.1093/annonc/mdw067 Open DOISearch in Google Scholar

[68] Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S. & O’Shaughnessy, J. et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J. Clin. Oncol. 36, 884–890 (2018). TrainaT.A. MillerK. YardleyD. A. EakleJ. SchwartzbergL. S. O’ShaughnessyJ. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer J. Clin. Oncol. 36 884 890 2018 Search in Google Scholar

[69] Weisman PS, Ng CK, Brogi E, et al. Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. Mod Pathol. 2016;29(5):476–488. doi:10.1038/modpathol.2016.39 WeismanPS NgCK BrogiE Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology Mod Pathol. 2016 29 5 476 488 10.1038/modpathol.2016.39 Open DOISearch in Google Scholar

[70] Lehmann BD, Bauer JA, Schafer JM, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014;16(4):406. Published 2014 Aug 8. doi:10.1186/s13058-014-0406-x LehmannBD BauerJA SchaferJM PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors Breast Cancer Res. 2014 16 4 406 Published 2014 Aug 8. 10.1186/s13058-014-0406-x Open DOISearch in Google Scholar

[71] Lehmann BD, Abramson VG, Sanders ME, et al. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2020;26(9):2111–2123. doi:10.1158/1078-0432.CCR-19-2170 LehmannBD AbramsonVG SandersME TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer Clin Cancer Res. 2020 26 9 2111 2123 10.1158/1078-0432.CCR-19-2170 Open DOISearch in Google Scholar

[72] Asghar US, Barr AR, Cutts R, et al. Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer. Clin Cancer Res. 2017;23(18):5561–5572. doi:10.1158/1078-0432.CCR-17-0369 AsgharUS BarrAR CuttsR Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer Clin Cancer Res. 2017 23 18 5561 5572 10.1158/1078-0432.CCR-17-0369 Open DOISearch in Google Scholar

[73] Ferguson DC, Mata DA, Tay TK, et al. Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations. Mod Pathol. 2022;35(3):396–402. doi:10.1038/s41379-021-00924-5 FergusonDC MataDA TayTK Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations Mod Pathol. 2022 35 3 396 402 10.1038/s41379-021-00924-5 Open DOISearch in Google Scholar

[74] Hickey TE, Irvine CM, Dvinge H, et al. Expression of androgen receptor splice variants in clinical breast cancers. Oncotarget. 2015;6(42):44728–44744. doi:10.18632/oncotarget.6296 HickeyTE IrvineCM DvingeH Expression of androgen receptor splice variants in clinical breast cancers Oncotarget. 2015 6 42 44728 44744 10.18632/oncotarget.6296 Open DOISearch in Google Scholar

[75] Hickey TE, Robinson JL, Carroll JS, Tilley WD. Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?. Mol Endocrinol. 2012;26(8):1252–1267. doi:10.1210/me.2012-1107 HickeyTE RobinsonJL CarrollJS TilleyWD Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol. 2012 26 8 1252 1267 10.1210/me.2012-1107 Open DOISearch in Google Scholar

[76] Schwartz CJ, Ruiz J, Bean GR, et al. Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior. Mod Pathol. 2023;36(5):100125. doi:10.1016/j.modpat.2023.100125 SchwartzCJ RuizJ BeanGR Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior Mod Pathol. 2023 36 5 100125 10.1016/j.modpat.2023.100125 Open DOISearch in Google Scholar